Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free DRMAW Stock Alerts

Dermata Therapeutics (DRMAW) Competitors

Dermata Therapeutics logo
$0.0006 0.00 (0.00%)
As of 08/17/2026
This is a fair market value price provided by Massive. Learn more.
Compare

DRMAW vs. DSYWW, PRENW, WALDW, PG, and UL

Should you buy Dermata Therapeutics stock or one of its competitors? Dermata Therapeutics's main competitors and comparable companies include Big Tree Cloud (DSYWW), Prenetics Global (PRENW), Waldencast (WALDW), Procter & Gamble (PG), and Unilever (UL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "personal care products" industry.

How does Dermata Therapeutics compare to Big Tree Cloud?

Big Tree Cloud (NASDAQ:DSYWW) and Dermata Therapeutics (NASDAQ:DRMAW) are both consumer staples companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Big Tree Cloud$2.02MN/AN/AN/AN/A
Dermata TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Big Tree CloudN/A N/A N/A
Dermata Therapeutics N/A N/A N/A

In the previous week, Dermata Therapeutics had 1 more articles in the media than Big Tree Cloud. MarketBeat recorded 1 mentions for Dermata Therapeutics and 0 mentions for Big Tree Cloud. Big Tree Cloud's average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company Overall Sentiment
Big Tree Cloud Neutral
Dermata Therapeutics Neutral

Summary

Big Tree Cloud and Dermata Therapeutics tied by winning 1 of the 2 factors compared between the two stocks.

How does Dermata Therapeutics compare to Prenetics Global?

Prenetics Global (NASDAQ:PRENW) and Dermata Therapeutics (NASDAQ:DRMAW) are both consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Company Net Margins Return on Equity Return on Assets
Prenetics GlobalN/A N/A N/A
Dermata Therapeutics N/A N/A N/A

In the previous week, Prenetics Global and Prenetics Global both had 1 articles in the media. Prenetics Global's average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prenetics Global
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Dermata Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prenetics Global$154.59MN/AN/AN/AN/A
Dermata TherapeuticsN/AN/AN/AN/AN/A

Summary

Prenetics Global beats Dermata Therapeutics on 1 of the 1 factors compared between the two stocks.

How does Dermata Therapeutics compare to Waldencast?

Waldencast (NASDAQ:WALDW) and Dermata Therapeutics (NASDAQ:DRMAW) are both consumer staples companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Company Net Margins Return on Equity Return on Assets
WaldencastN/A N/A N/A
Dermata Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Waldencast$272.07MN/AN/AN/AN/A
Dermata TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Dermata Therapeutics had 1 more articles in the media than Waldencast. MarketBeat recorded 1 mentions for Dermata Therapeutics and 0 mentions for Waldencast. Waldencast's average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company Overall Sentiment
Waldencast Neutral
Dermata Therapeutics Neutral

Summary

Waldencast and Dermata Therapeutics tied by winning 1 of the 2 factors compared between the two stocks.

How does Dermata Therapeutics compare to Procter & Gamble?

Dermata Therapeutics (NASDAQ:DRMAW) and Procter & Gamble (NYSE:PG) are both consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Procter & Gamble has a net margin of 18.44% compared to Dermata Therapeutics' net margin of 0.00%. Procter & Gamble's return on equity of 31.36% beat Dermata Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Procter & Gamble 18.44%31.36%13.09%

65.8% of Procter & Gamble shares are owned by institutional investors. 0.2% of Procter & Gamble shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Procter & Gamble has a consensus target price of $161.52, indicating a potential upside of 11.57%. Given Procter & Gamble's stronger consensus rating and higher probable upside, analysts plainly believe Procter & Gamble is more favorable than Dermata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dermata Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Procter & Gamble
0 Sell rating(s)
11 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.54

In the previous week, Procter & Gamble had 96 more articles in the media than Dermata Therapeutics. MarketBeat recorded 97 mentions for Procter & Gamble and 1 mentions for Dermata Therapeutics. Procter & Gamble's average media sentiment score of 1.56 beat Dermata Therapeutics' score of 0.00 indicating that Procter & Gamble is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dermata Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Procter & Gamble
89 Very Positive mention(s)
8 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Procter & Gamble has higher revenue and earnings than Dermata Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
Procter & Gamble$87.03B3.87$16.05B$6.6221.87

Summary

Procter & Gamble beats Dermata Therapeutics on 11 of the 11 factors compared between the two stocks.

How does Dermata Therapeutics compare to Unilever?

Dermata Therapeutics (NASDAQ:DRMAW) and Unilever (NYSE:UL) are both consumer staples companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

In the previous week, Unilever had 6 more articles in the media than Dermata Therapeutics. MarketBeat recorded 7 mentions for Unilever and 1 mentions for Dermata Therapeutics. Unilever's average media sentiment score of 1.21 beat Dermata Therapeutics' score of 0.00 indicating that Unilever is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dermata Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Unilever
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Unilever has higher revenue and earnings than Dermata Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
Unilever$50.62B2.73$10.71BN/AN/A

9.7% of Unilever shares are owned by institutional investors. 1.0% of Unilever shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Unilever has a consensus price target of $65.55, indicating a potential upside of 2.18%. Given Unilever's stronger consensus rating and higher probable upside, analysts plainly believe Unilever is more favorable than Dermata Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dermata Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Unilever
2 Sell rating(s)
6 Hold rating(s)
2 Buy rating(s)
2 Strong Buy rating(s)
2.33

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Unilever N/A N/A N/A

Summary

Unilever beats Dermata Therapeutics on 9 of the 9 factors compared between the two stocks.

Get Dermata Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DRMAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DRMAW vs. The Competition

Export
MetricDermata TherapeuticsPersonal Care Products IndustryConsumer Staples SectorNASDAQ Exchange
Market CapN/A$23.48B$15.97B$12.83B
Dividend YieldN/A4.29%3.21%10.78%
P/E RatioN/A19.2213.5824.21
Price / SalesN/A13.25262,949.3090.25
Price / CashN/A17.1556.1936.90
Price / BookN/A3.004.986.42
Net IncomeN/A$1.13B$836.78M$348.89M
7 Day PerformanceN/A0.71%0.26%0.08%
1 Month PerformanceN/A2.24%2.22%3.88%
1 Year PerformanceN/A-18.64%13.47%16.98%

Dermata Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DRMAW
Dermata Therapeutics
N/A$0.00
flat		N/A-97.1%$0.00N/AN/A8
DSYWW
Big Tree Cloud
N/A$0.02
-18.8%		N/A-6.8%$0.00$2.02MN/A82
PRENW
Prenetics Global
N/A$0.01
-16.3%		N/AN/A$0.00$120.07MN/A1
WALDW
Waldencast
N/A$0.02
-9.4%		N/A-33.3%$0.00$272.07MN/A284
PG
Procter & Gamble
4.3034 of 5 stars		$144.30
+0.6%		$161.52
+11.9%		-8.7%$335.78B$87.03B21.82104,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DRMAW) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel